タバタ　ツトム   TABATA Tsutomu   田畑　務    所属   医学部 医学科（東京女子医科大学病院）    職種   教授・基幹分野長
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Prognostic Benefit of ≥6 Cycles of Neoadjuvant Chemotherapy for Advanced Ovarian, Tubal, and Peritoneal Cancers.
掲載誌名	正式名：Anticancer research 略　 称：Anticancer Res ISSNコード：17917530/02507005
掲載区分	国外
巻・号・頁	41(8),pp.4157-4161
著者・共著者	Kondo Eiji, Nimura Ryo, Maki Shintaro, Kaneda Michiko, Nii Masafumi, Yoshida Kenta, Tabata Tsutomu, Ikeda Tomoaki
発行年月	2021/08
概要	BACKGROUND/AIM:A higher number of neoadjuvant chemotherapy (NACT) cycles translate to a lower risk of morbidity and mortality, but few studies have analyzed the prognostic impact of >4 cycles of NACT.PATIENTS AND METHODS:Overall, 52 patients [31 patients, NACT plus interval debulking surgery (IDS); 21 patients, NACT alone owing to progressive disease] who underwent NACT between January 2008 and December 2014 were evaluated.RESULTS:In total, 6, 7-10, and 11-18 cycles of NACT were performed in 52.3%, 27.3%, and 20.5% of the patients, respectively. The median overall survival was 76.0 months (range=36.0-94.0 months), and the median progression-free survival was 26.0 months (range=18.0-54.0 months) in the NACT plus IDS group.CONCLUSION:At least six cycles of NACT plus IDS are associated with a lower rate of multi-organ resection and a high rate of complete resection or optimal (<1 cm) following IDS.
DOI	10.21873/anticanres.15219
PMID	34281887